Home > Search Results

Results: 15

Clear

The fixed combination of emtricitabine / rilpivirine / tenofovir alafenamide (trade name: Odefsey) has been approved in Germany since June 2016 for the treatment of type 1 HIV in adults and children aged 12 and over.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: November 3, 2016

In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of emtricitabine / tenofovir alafenamide compared to the standard treatments for adults with HIV who have had treatment before. Individualized therapy is an option for these patients. This looks at which treatments were tried before and why they were discontinued. For instance, the previous treatment may have been ineffective or caused very severe side effects.The manufacturer provided provisional results from two studies involving patients who had already taken standard HIV drugs.In one study, 306 people who had been taking standard HIV drugs were instead given the fixed-dose combination emtricitabine / tenofovir alafenamide. The remaining 153 people continued taking the standard combination emtricitabine / tenofovir disoproxil. Both groups were also given elvitegravir and cobicistat.In the other study, 334 people stopped taking the standard drugs and instead took emtricitabine / tenofovir alafenamide, while the comparison group (334 people) continued treatment with emtricitabine / tenofovir disoproxil. These two groups received additional drugs as well.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: September 8, 2016

The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and adolescents living with HIV around the world. Deciding which treatment regimen to begin for first‐line treatment in ART‐naïve patients, however, remains a significant challenge. Two commonly used medications are tenofovir (TDF) and zidovudine (AZT). The purpose of this review was to assess which of these two medications was the best for initial treatment for people living with HIV, and through our search we identified two randomised controlled trials. We did not find any critical difference between the two medications in regards to serious adverse events or virologic response, but did find that TDF is superior to AZT in terms of immunologic response and adherence and more frequent emergence of resistance. However, these two studies are not directly comparable because they used two related different drugs in addition to TDF and AZT. Future studies and recommendations should focus on specific toxicities and tolerability when comparing these two medications.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

The drug tenofovir alafenamide (trade name: Vemlidy) has been approved in Germany since January 2017 for the treatment of chronic hepatitis B. It is an option for adults and teenagers over the age of 12.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 27, 2017

Patients starting their first HIV treatment are often given efavirenz in combination with two other drugs. Emtricitabine and tenofovir are one of several pairs of drugs that can be used in this way.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of rilpivirine taken in a fixed-dose combination with emtricitabine / tenofovir (trade name: Eviplera), compared with the fixed-dose combination efavirenz plus emtricitabine / tenofovir. Three studies were available to IQWiG.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: April 20, 2017

The fixed combination emtricitabine / tenofovir alafenamide (trade name: Descovy) has been approved in Germany since April 2016 for the treatment of human immunodeficiency virus (HIV) type 1 infection in adults and adolescents over 12 years of age. It is combined with other treatments.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: September 8, 2016

This review evaluated the effects of giving people at high risk for HIV infection drugs to prevent infection (called antiretroviral pre‐exposure prophylaxis, or PrEP). We found six randomised controlled trials that assessed the effects of oral tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) versus placebo; TDF versus placebo, and daily TDF‐FTC versus intermittent TDF‐FTC. One of the trials had three study arms (TDF, TDF‐FTC and placebo arm). The trials were carried out amongst different risk groups, including HIV‐uninfected men who have sex with men, people in serodiscordant sexual relationships where one partner is infected and the other is not, and other high risk men and women. The findings suggests that the use of TDF alone or TDF+FTC reduces the risk of becoming infected with HIV. However, further studies are need to evaluate the method of administration (daily versus intermittent dosing), long‐term safety and cost effectiveness of PrEP in different risk groups and settings.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Microbicide research has had disappointing outcomes during the last two decades as most microbicides have not shown evidence that they can prevent acquisition of sexually transmitted infections (STIs), including human immunodeficiency virus (HIV). However, a recent small preliminary study suggests that microbicides containing the antiretroviral drug tenofovir may prevent acquisition of HIV and herpes simplex virus infection in women; but further research is needed to assess the generalisability of these findings. Therefore, there is not enough evidence to recommend topical microbicides for HIV or STI prevention at present.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

In 2014 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed which advantages and disadvantages dolutegravir / abacavir / lamivudine has compared with previous standard therapies in people who are having initial treatment for HIV. A study looking at efavirenz provided results which were used for a comparison of the two drugs. The patient group that was treated using efavirenz also received the fixed combination tenofovir / emtricitabine.A total of 844 people participated in the study, with one half of them receiving dolutegravir / abacavir / lamivudine and the other half efavirenz / tenofovir / emtricitabine. All data was analyzed after 20 months.The following results apply to people who have not yet taken any other medication to treat HIV.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 2, 2015

Rilpivirine has been approved in Germany since November 2011 as a single agent (trade name: Edurant) and in a fixed-dose combination with emtricitabine and tenofovir (trade name: Eviplera) for the treatment of HIV type 1 in some adults.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 29, 2017

Patients starting their first HIV treatment are often given efavirenz in combination with two other drugs. Emtricitabine and tenofovir are one of several pairs of drugs that can be used in this way.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of rilpivirine as a single drug (trade name: Edurant) taken together with two other drugs, compared with efavirenz in combination with two other drugs. The results of 815 patients were analyzed. Almost three quarters of them took rilpivirine with emtricitabine and tenofovir, and about one quarter took rilpivirine with zidovudine and lamivudine. Only a few had used rilpivirine plus abacavir and lamivudine.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: April 20, 2017

In the spring of 2014 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed which advantages and disadvantages dolutegravir has compared with previous standard therapies in people who are having initial treatment for HIV. The assessment was based on two relevant studies comparing dolutegravir with efavirenz. One study compared two groups who took both dolutegravir and a fixed combination of either abacavir / lamivudin or tenofovir / emtricitabin. In the other study, one group used dolutegravir with the fixed combination of abacavir / lamivudin, while the other group was given the fixed combination of efavirenz / tenofovir / emtricitabin.The first study included 103 people in its analysis, and the second study involved 844 participants. The study data were analyzed after 96 weeks.The following results apply to people who have not yet taken any other medication to treat HIV.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 15, 2014

Since early 2011, the added benefit of most medications containing new active ingredients must be assessed as soon as they enter the market in Germany. The most important results of the IQWiG reviews are summarized here.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: August 24, 2017

The fixed combination of dolutegravir / abacavir / lamivudine (trade name: Triumeq) has been approved in Germany since September 2014 for the treatment of HIV infections in adults and adolescents above 12 years of age weighing a minimum of 40 kilograms.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 2, 2015

Dolutegravir (trade name: Tivicay) has been approved in Germany since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infection in adults and children over 12 years of age.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 27, 2017

Systematic Reviews in PubMed

See all (177)...

Systematic Review Methods in PubMed

See all (2)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...